PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
暂无分享,去创建一个
Francesca Molinari | Michele Nichelatti | L. Mazzucchelli | A. Bardelli | F. Di Nicolantonio | M. Nichelatti | F. Molinari | M. Frattini | S. Veronese | A. Sartore-Bianchi | S. Siena | M. Martini | Luca Mazzucchelli | Federica Di Nicolantonio | Milo Frattini | Alberto Bardelli | Piercarlo Saletti | Andrea Sartore-Bianchi | Salvatore Siena | Silvio Veronese | P. Saletti | Sara De Dosso | Miriam Martini | Salvatore Artale | S. Artale | S. De Dosso
[1] A. Jemal,et al. Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.
[2] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[3] Silvia Benvenuti,et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.
[4] Sabine Tejpar,et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience , 2008 .
[5] Hanina Hibshoosh,et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.
[6] Carlo Rago,et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.
[7] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[8] Marc Peeters,et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Fukuda,et al. European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .
[10] F. Cavalli,et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients , 2007, British Journal of Cancer.
[11] Sanjay Goel,et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. , 2008, Cancer research.
[12] D. Jäger,et al. [Systemic therapy for colorectal cancer]. , 2005, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.
[13] M. Ringnér,et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.
[14] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[16] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[17] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[18] Silvia Benvenuti,et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.
[19] Hiroyuki Konishi,et al. The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.
[20] C. Bokemeyer,et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience , 2008 .
[21] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[22] Richard L Schilsky,et al. Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.
[23] Michael J. Fry,et al. Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.